REFERENCES
- Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:192–197.
- Mildvan D, Creagh T, Leitz G. Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients: findings of the Anemia Prevalence Study. Curr Med Res Opin. 2007;23:343–355.
- Keiser P, Rademacher S, Smith J, Skiest D. G-CSF associ-ation with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection. Int J STD AIDS. 1998;9:394–399.
- Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance proj-ect. Blood. 1998;91:301–308.
- Ayers KM, Tucker WE Jr, Hajian G, de Miranda P. Nonclinical toxicology studies with zidovudine: acute, subacute, and chronic toxicity in rodents, dogs, and monkeys. Fundam Appl Toxicol. 1996;32:129–139.
- Ippolito G, Puro V. Zidovudine toxicity in uninfected health-care workers. Italian Registry of Antiretroviral Prophylaxis. Am J Med. 1997;102:58–62.
- Gatell JM, Gonzalez-Lahoz J, Clotet B, et al. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddl Iberian Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:249–258.
- Spruance SL, Pavia AT, Peterson D, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb A1454-010 Study Group. Ann Intern Med. 1994;120:360–368.
- Vella S, Floridia M, Daily LG, et al. A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:462–469.
- Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2001;26:28–35.
- Molina JM, Bentata M, Garré M, et al, and the ALIZE Study Group. Hematological benefit of switching from regimens combining protease inhibitors and zidovudine plus lamivu-dine to once-daily emtricitabine, didanosine and efavirenz. A sub-study of the ANRS 099 ALIZE trial. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22–25, 2005; Boston, MA. Abstract 830.
- Ten Berg MJ, Huisman A, van den Bemt PM, Schobben AF, Egberts AC, van Solinge WW. Linking laboratory and medication data: new opportunities for pharmacoepide-miological research. Clin Chem Lab Med. 2007;45:13–19.
- Gonzalez-Garcia JJ, Berenguer J, Condes E, et al, and the GESIDA 50/06 Study Group. The use of TDF+ 3TC/ FTC is associated with an improved response to pegylated interferon +ribavirin in HIV/HCV-co-infected patients receiving HAART The Gesida 50/06 Study. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3–6, 2008; Boston, MA. Abstract 1076.
- DeJesus E, Ruane P, McDonald C, et al. Impact of switch-ing virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials. 2008;9:103–114.
- Arranz Caso JA, Sanchez MC, Garcia TJ. Effect of highly active anti retroviral therapy on thrombocytopenia in patients with HIV infection. N Engl J Med. 1999;341:1239–1240.